Details

Last Funding Type

Corporate Round

Last Funding Money Raised

€25M

Industries

Bioinformatics,Biopharma,Biotechnology,Genetics,Pharmaceutical

Founded date

Jan 1, 2009

Number Of Employee

101 - 250

Operating Status

Active

ETHRIS develops mRNA therapeutics with a focus on respiratory diseases and vaccines. ETHRIS possesses an enabling LNP delivery and mRNA modification platform for transcript Therapies. SNIM®RNAis a first-in-class biopharmaceutical which provide a compelling alternative for recombinant protein or gene therapies. SNIM®RNAs encode therapeutic proteins to be produced in the patient‘s body and overcome short duration effects of recombinant proteins. SNIM®RNA Transcript Therapy is a new option for a broad variety of diseases, either acquired or genetically predetermined, lifestyle- or age-related, rare or frequent.